Page 32 - 《中国药科大学学报》2026年第1期

26 学报 Journal of China Pharmaceutical University 2026, 57(1): 19 − 27 第 57 卷

原呈递细胞活性并引发系统性抗肿瘤免疫。 future prospects[J]. Front Immunol, 2024, 15: 1485546.
[11] Yang JH, Luo ZY, Ma JY, et al. A next-generation STING ago-
4 展 望 nist MSA-2: from mechanism to application[J]. J Control Re-
lease, 2024, 371: 273-287.
STING ISAC 作为一种新型免疫治疗策略，通 [12] Xu Y, Xiong Y. Targeting STING signaling for the optimal can-
过靶向递送克服了小分子 STING 激动剂选择性低 cer immunotherapy[J]. Front Immunol, 2024, 15: 1482738.
[13] Huang RL, Ning Q, Zhao JH, et al. Targeting STING for can-
的瓶颈，已有多项临床前和早期临床试验展现出
cer immunotherapy: from mechanisms to translation[J]. Int Im-
STING ISAC 药物良好的抗肿瘤活性和安全性，未 munopharmacol, 2022, 113(Pt A): 109304.
来有望更多的 STING ISAC 药物进入临床试验并 [14] Fu ZW, Li SJ, Han SF, et al. Antibody drug conjugate: the “bi-
ological missile” for targeted cancer therapy[J]. Signal Trans-
获批上市。然而 STING ISAC 药物的发展也面临
duct Target Ther, 2022, 7: 93.
一些挑战，目前亟须解决两大问题：一是靶点选择 [15] Bukhalid RA, Duvall JR, Cetinbas NM, et al. Abstract 6706:
特异性不足可能导致正常组织 STING 通路非预期 Systemic administration of STING agonist antibody-drug conju-
gates elicit potent anti-tumor immune responses with minimal
激活；二是不同肿瘤微环境中 STING 信号响应异
induction of circulating cytokines[J]. Cancer Res, 2020,
质性可能影响疗效，未来可通过开发肿瘤微环境响 80(16_Supplement): 6706.
应型连接子或双靶点递送策略进一步优化。 [16] Mahalingaiah PK, Ciurlionis R, Durbin KR, et al. Potential
mechanisms of target-independent uptake and toxicity of anti-
总体而言，随着研究技术的不断进步和研究的
body-drug conjugates[J]. Pharmacol Ther, 2019, 200: 110-125.
深入， STING ISAC 药物有望成为肿瘤治疗领域一 [17] Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadeh R,
大重要突破，为肿瘤患者带来希望。 et al. Antibody-drug conjugates: possibilities and challenges[J].
Avicenna J Med Biotechnol, 2019, 11(1): 3-23.
[18] Maecker H, Jonnalagadda V, Bhakta S, et al. Exploration of the
References
antibody-drug conjugate clinical landscape[J]. MAbs, 2023,
[1] Ackerman SE, Pearson CI, Gregorio JD, et al. Immune-stimu- 15(1): 2229101.
lating antibody conjugates elicit robust myeloid activation and [19] Ramanjulu JM, Scott Pesiridis G, Yang JS, et al. Design of ami-
durable antitumor immunity[J]. Nat Cancer, 2021, 2(1): 18-33. dobenzimidazole STING receptor agonists with systemic activi-
[2] Demaria O, Vivier E. ISACs take a toll on tumors[J]. Nat Can- ty[J]. Nature, 2018, 564(7736): 439-443.
cer, 2021, 2(1): 12-13. [20] Wang ZJ, Li HX, Gou LT, et al. Antibody-drug conjugates: Re-
[3] Duvall JR, Thomas JD, Bukhalid RA, et al. Discovery and opti- cent advances in payloads[J]. Acta Pharm Sin B, 2023, 13(10):
mization of a STING agonist platform for application in anti- 4025-4059.
body drug conjugates[J]. J Med Chem, 2023, 66(15): 10715- [21] Zhang H, You QD, Xu XL. Targeting stimulator of interferon
10733. genes (STING): a medicinal chemistry perspective[J]. J Med
[4] Malli Cetinbas N, Monnell T, Soomer-James J, et al. Tumor Chem, 2020, 63(8): 3785-3816.
cell-directed STING agonist antibody-drug conjugates induce [22] Vavřina Z, Perlíková P, Milisavljević N, et al. Design, synthe-
type III interferons and anti-tumor innate immune responses[J]. sis, and biochemical and biological evaluation of novel 7-deaza-
Nat Commun, 2024, 15(1): 5842. purine cyclic dinucleotide analogues as STING receptor ago-
[5] Zheng JY, Mo JL, Zhu T, et al. Comprehensive elaboration of nists[J]. J Med Chem, 2022, 65(20): 14082-14103.
the cGAS-STING signaling axis in cancer development and im- [23] Xie X, Liu JY, Wang XW. Design, synthesis and biological
munotherapy[J]. Mol Cancer, 2020, 19(1): 133. evaluation of (2', 5' and 3'5'-linked) cGAMP analogs that acti-
[6] Samson N, Ablasser A. The cGAS-STING pathway and vate stimulator of interferon genes (STING)[J]. Molecules,
cancer[J]. Nat Cancer, 2022, 3(12): 1452-1463. 2020, 25(22): 5285.
[7] Pan XH, Zhang WX, Guo HJ, et al. Strategies involving STING [24] Cong XY, Yuan ZL, Du YJ, et al. Crystal structures of porcine
pathway activation for cancer immunotherapy:mechanism and STING CBD -CDN complexes reveal the mechanism of ligand
agonists[J]. Biochem Pharmacol, 2023, 213: 115596. recognition and discrimination of STING proteins[J]. J Biol
[8] Yum S, Li MH, Fang Y, et al. TBK1 recruitment to STING ac- Chem, 2019, 294(30): 11420-11432.
tivates both IRF3 and NF-κB that mediate immune defense [25] Appleman VA, Matsuda A, Ganno ML, et al. Selective STING
against tumors and viral infections[J]. Proc Natl Acad Sci USA, activation in intratumoral myeloid cells via CCR2-directed anti-
2021, 118(14): e2100225118. body-drug conjugate TAK-500[J]. Cancer Immunol Res, 2025,
[9] Zhang XW, Bai XC, Chen ZJ. Structures and mechanisms in the 13(5): 661-679.
cGAS-STING innate immunity pathway[J]. Immunity, 2020, [26] Diamond JR, Henry JT, Falchook GS, et al. Phase 1a/1b study
53(1): 43-53. design of the novel STING agonist, immune-stimulating anti-
[10] Wang B, Yu WP, Jiang HF, et al. Clinical applications of body-conjugate (ISAC) TAK-500, with or without pem-
STING agonists in cancer immunotherapy: current progress and brolizumab in patients with advanced solid tumors[J]. J Clin